ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: 83 years Female

Specimen Collected: 23-Jun-22 09:50

Pemphigoid Antibody Panel	**|Received: 23-Jun-22 09:56**		**Report/Verified: 23-Jun-22 10:05**
Procedure	**Result**	**Units**	**Reference Interval**
EER Pemphigoid Antibody Panel	See Note [f1]		

Pemphigoid Antibody Panel	**|Received: 23-Jun-22 15:30**		**Report/Verified: 23-Jun-22 17:42**
Procedure	**Result**	**Units**	**Reference Interval**
Pemphigoid Antibody Panel	See Note [f2]		

Result Footnote

f1: EER Pemphigoid Antibody Panel
Authorized individuals can access the ARUP
Enhanced Report using the following link:

f2: Pemphigoid Antibody Panel
CLINICAL INFORMATION
Tense blisters on urticarial base with pruritus. Presumptive diagnosis is bullous pemphigoid.

Specimen Details
S22-IP0000535 - Serum; Collected: 6/23/2022; Received: 6/23/2022

DIAGNOSTIC INTERPRETATION

Pemphigoid Antibody Panel monitoring, consistent with pemphigoid

(See Results, Comments, and Previous and Current Test Results Summary Chart with Graph of ELISA results in the Enhanced Electronic Report/EELR and/or available upon request)

RESULTS
Indirect Immunofluorescence (IIF)

Basement Membrane Zone (BMZ) IgG, IgG4, and IgA Antibodies

IgG: Negative, monkey esophagus substrate
Negative, human split skin substrate

IgG4: Detected, titer 1:10 (Borderline), monkey esophagus substrate
Positive, epidermal localization (roof), titer 1:20 (H), human split skin substrate

IgA: Negative, monkey esophagus substrate
Negative, human split skin substrate

Reference Range:
Negative - Titer less than 1:10
Borderline - Titer 1:10
Positive (H) - Titer greater than 1:10

Localization Pattern on Human BMZ Split Skin:
Epidermal (roof) or combined epidermal-dermal (roof and floor) IgG and/or IgG4 BMZ antibodies

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Result Footnote

f2: Pemphigoid Antibody Panel
= pemphigoid (including pemphigoid gestationis, bullous pemphigoid, mucous membrane pemphigoid)

Dermal (floor) IgG and/or IgG4 BMZ antibodies = epidermolysis bullosa acquisita or bullous lupus erythematosus or anti-laminin-332 pemphigoid or anti-p200 (laminin gamma-1) pemphigoid or another rare pemphigoid subtype

Epidermal (roof), combined epidermal-dermal (roof and floor), or, dermal (floor) IgA BMZ antibodies = linear IgA disease (including linear IgA bullous dermatosis and chronic bullous disease of childhood)

Enzyme-Linked Immunosorbent Assay (ELISA)

Bullous Pemphigoid (BP)180 and BP230 IgG Antibodies

IgG BP180 antibody level: 49 U/mL (H)

Reference Range:
Normal (negative) = Less than 9 U/mL
Increased (H) (positive) = 9 U/mL and greater

IgG BP230 antibody level: 3 U/mL

Reference Range:
Normal (negative) = Less than 9 U/mL
Increased (H) (positive) = 9 U/mL and greater

(H) = high/positive
U = antibody level in ELISA units

COMMENTS

Specific

The findings, demonstrating positive IgG4 basement membrane zone antibody reactivity with epidermal localization on split skin substrate by indirect immunofluorescence and an increased IgG BP180 antibody level by ELISA, provide support for the diagnosis of pemphigoid. Previous testing showed similar findings, supporting the diagnosis of pemphigoid including pemphigoid variants, and also a normal IgG type VII collagen antibody level by ELISA on one determination. See chart for summary of previous and current basement membrane zone antibody test results at end of report (below); a graph of the ELISA results is available in the Enhanced Electronic Report/EELR and/or available upon request by contacting ARUP Client Services at 1-800-242-2787, option 2, and ask to speak with the Immunodermatology Laboratory at the University of Utah regarding patient results.

Detection, levels, and patterns of diagnostic antibodies may fluctuate with disease manifestations, and IgG BP180 antibody levels correlate with disease activity in some patients with pemphigoid. Clinical correlation is needed, including treatment status, with consideration for continued monitoring of serum antibody profiles by indirect immunofluorescence and antibody levels by ELISAs to aid in assessing disease expression and activity, including response to therapy.

Result Footnote

f2: Pemphigoid Antibody Panel

General

Approximately 80 percent of patients with bullous pemphigoid and epidermolysis bullosa acquisita have positive IgG and/or IgG4 antibodies to basement membrane zone components in their sera detected by indirect immunofluorescence. Approximately 50 percent of patients with mucous membrane/cicatricial pemphigoid demonstrate antibodies to basement membrane zone components detected by indirect immunofluorescence. The immunoglobulin class of basement membrane zone antibodies and pattern of antibody localization on split skin substrate (also known as salt split skin) distinguish the diseases. IgG4 subclass reactivity by indirect immunofluorescence may be more sensitive than IgG in some patients with pemphigoid and epidermolysis bullosa acquisita.

Positive serum IgA epithelial basement membrane zone antibodies are highly specific diagnostic markers for linear IgA disease and are present in up to 80 percent of patients with linear IgA bullous dermatosis. Titers of positive IgA basement membrane zone antibodies may be useful markers in following disease expression and activity. IgA basement membrane zone antibodies may be found in variant presentations of mucous membrane pemphigoid and epidermolysis bullosa acquisita. IgA basement membrane zone antibodies may be co-expressed with IgG basement membrane zone antibodies in some patients with pemphigoid including mucous membrane/cicatricial pemphigoid. When co-expressed, the presence of two antibody classes with reactivity toward basement membrane zone may have implications for disease severity and treatment considerations.

Major molecular structures in the basement membrane zone to which IgG pemphigoid antibodies bind have been identified and termed "BP180" for a 180 kDa bullous pemphigoid antigen (also known as bullous pemphigoid antigen 2, BPAG2, or type XVII collagen, COL17) and "BP230" for a 230 kDa bullous pemphigoid antigen (also known as bullous pemphigoid antigen 1, BPAG1). BP180 is a transmembrane component of the basement membrane zone with collagen-like domains and is a principal antigenic target. BP230 is located in the hemidesmosomal plaque of basal cells in the epidermis. Serum levels of IgG BP180 and IgG BP230 antibodies are determined by ELISA, and serum levels of IgG BP180 antibodies may correlate with disease activity in pemphigoid, diminishing with treatment response. Up to 7 percent of individuals who do not have pemphigoid, including patients with other immunobullous diseases, have increased levels of IgG BP180 and/or BP230 antibodies by ELISAs. Patients with pemphigoid may show reactivity to multiple basement membrane zone components in addition to or other than the BP180 and BP230 epitopes displayed in the tested ELISAs. Type VII collagen is a component of anchoring fibrils within epithelial basement membrane zone (skin and mucous membranes), and patients with epidermolysis bullosa acquisita characteristically develop IgG antibodies to type VII collagen.

TESTING METHODS

Indirect Immunofluorescence (IIF)

IgG, IgG4, and IgA Epithelial Basement Membrane Zone (BMZ) Antibodies

Patient serum is progressively diluted beginning at 1:5 in three two-fold screening dilutions, layered on sections of human skin split at the basement membrane zone and monkey esophagus substrates, and reacted with fluorescein isothiocyanate (FITC)-conjugated antibodies to IgG and IgA. When positive, the serum is further diluted in two-fold reductions to the limiting dilution of antibody detection or to a maximum dilution of 1:40,960. The limiting-dilution, end-point titer is reported for each substrate, and the pattern of staining on split skin substrate also is reported. FITC-conjugated anti-IgG4 is tested to increase test sensitivity (maximum serum dilution of 1:20). This indirect immunofluorescence testing was developed and its performance characteristics determined by the Immunodermatology Laboratory at the University of Utah. It has not been cleared or approved by the FDA (US Food and Drug Administration). FDA clearance or approval currently is not required for this testing performed in a CLIA-certified

Result Footnote

f2: Pemphigoid Antibody Panel
laboratory (Clinical Laboratory Improvement Amendments) and intended for clinical use. [Indirect immunofluorescence, three antibodies on two substrates (IIF X 6)]

Enzyme-Linked Immunosorbent Assays (ELISA)

IgG BP180 and IgG BP230 serum antibody levels determined by U.S. Food and Drug Administration (FDA)-approved ELISAs (Mesacup, MBL BION). [Two ELISAs]

TEST RESULTS SUMMARY CHART
Basement Membrane Zone (BMZ) Antibodies

Serum Number	Date of Specimen	IgG and IgG4 BMZ Titers	IgA BMZ Titers	BP 180	BP 230	Col VII
20-0234	03/26/20	IgG ME Neg IgG SS Neg IgG4 ME 1:5 IgG4 SS Epi, 1:20	ME Neg SS Neg	52	4	NA
20-2225	11/15/20	IgG ME Neg IgG SS Neg IgG4 ME 1:10 IgG4 SS Epi, 1:20	ME Neg SS Neg	57	4	NA
21-0025	01/06/21	IgG ME Neg IgG SS Epi, 1:10 IgG4 ME 1:20 IgG4 SS Epi, >1:20	ME Neg SS Neg	67	6	NA
21-0654	05/20/21	IgG ME Neg IgG SS Epi, 1:20 IgG4 ME 1:10 IgG4 SS Epi, 1:20	ME Neg SS Neg	59	5	NA
21-0722	07/24/21	IgG ME Neg IgG SS Epi, 1:10 IgG4 ME 1:10 IgG4 SS Epi, 1:20	ME Neg SS Neg	53	4	2
22-0513	06/22/22	IgG ME Neg IgG SS Neg IgG4 ME 1:10 IgG4 SS Epi, 1:20	ME Neg SS Neg	49	3	NA

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Result Footnote

f2: Pemphigoid Antibody Panel

ELISA Reference Ranges:

IgG BP180 and IgG BP230 Antibody Levels
Normal (negative) = Less than 9 U/mL
Increased (H) (positive) = 9 U/mL and greater

IgG Type VII Collagen Antibody Level
Normal (negative) = Less than 7 U/mL
Slightly increased (H) (positive) = 7-8 U/mL
Increased (H) (positive) = 9 U/mL and greater

Chart Key:

IgG BMZ = IgG basement membrane zone (BMZ) antibodies by indirect immunofluorescence
IgG4 BMZ = IgG4 basement membrane zone (BMZ) antibodies by indirect immunofluorescence
IgA BMZ = IgA basement membrane zone (BMZ) antibodies by indirect immunofluorescence

ME = Antibody absence (negative) or antibody presence (positive endpoint titer) on monkey esophagus (ME) substrate
SS = Antibody absence (negative) or antibody presence (positive pattern and endpoint titer) on split skin (SS) substrate

Epi = epidermal localization (roof) on split skin substrate (IgG - pemphigoid including bullous pemphigoid, some mucous membrane pemphigoid, and other pemphigoid variants; IgA - linear IgA disease including linear IgA bullous dermatosis and chronic bullous disease of childhood)
Derm = dermal localization (floor) on split skin substrate (IgG - epidermolysis bullosa acquisita, bullous lupus erythematosus, anti-laminin-332 pemphigoid, anti-p200 (laminin gamma-1) pemphigoid, other rare pemphigoid subtypes; IgA - linear IgA disease including linear IgA epidermolysis bullosa acquisita)
Comb = combined epidermal-dermal localization (roof and floor) on split skin substrate (IgG - pemphigoid and pemphigoid variants; IgA - linear IgA disease)

BP180 = IgG BP180 antibody level (U/mL) by ELISA
BP230 = IgG BP230 antibody level (U/mL) by ELISA
Col VII = IgG Collagen VII antibody level (U/mL) by ELISA

Neg = Negative
NA = Not Assayed

Result Footnote

f2: Pemphigoid Antibody Panel

Electronically signed by Kristin M. Leiferman, MD, on 06/23/22 at 5:42 PM.
Performed At: IMMUNODERMATOLOGY LABORATORY
417 S. WAKARA WAY, SUITE 2151
SALT LAKE CITY, UT 84108
Medical Director: JOHN JOSEPH ZONE, MD
CLIA Number: 46D0681916